当前位置: X-MOL 学术Infect. Agents Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Circulating cell‐free epstein–barr virus DNA levels and clinical features in Moroccan patients with nasopharyngeal carcinoma
Infectious Agents and Cancer ( IF 3.7 ) Pub Date : 2021-02-18 , DOI: 10.1186/s13027-021-00353-8
Amina Gihbid , Raja Benzeid , Abdellah Faouzi , Jalal Nourlil , Nezha Tawfiq , Nadia Benchakroun , Amal Guensi , Karima Bendahhou , Abdellatif Benider , Naima El Benna , Imane Chaoui , Rachida Cadi , Mohammed El Mzibri , Meriem Khyatti

The identification of effective prognosis biomarkers for nasopharyngeal carcinoma (NPC) is crucial to improve treatment and patient outcomes. In the present study, we have attempted to evaluate the correlation between pre-treatment plasmatic Epstein-Barr virus (EBV) DNA load and the conventional prognostic factors in Moroccan patients with NPC. The present study was conducted on 121 histologically confirmed NPC patients, recruited from January 2017 to December 2018. Circulating levels of EBV DNA were measured before therapy initiation using real-time quantitative PCR. Overall, undifferentiated non-keratinizingcarcinoma type was the most common histological type (90.1 %), and 61.8 % of patients were diagnosed at an advanced disease stage (IV). Results of pre-treatment plasma EBV load showed that 90.9 % of patients had detectable EBV DNA, with a median plasmatic viral load of 7710 IU/ml. The correlation between pre-treatment EBV DNA load and the conventional prognostic factors showed a significant association with patients’ age (p = 0.01), tumor classification (p = 0.01), lymph node status (p = 0.003), metastasis status (p = 0.00) and overall cancer stage (p = 0.01). Unexpectedly, a significant higher level of pre-treatment EBV DNA was also found in plasma of NPC patients with a family history of cancer (p = 0.04). The risk of NPC mortality in patients with high pretreatment EBVDNA levels was significantly higher than that of those with low pre-treatment plasma EBV-DNA levels (p < 0.05). Furthermore, patients with high pre-treatment EBV-DNA levels (≥ 2000, ≥ 4000) had a significant low overall survival (OS) rates (p < 0.05). Interestingly, lymph node involvement, metastasis status and OS were found to be the most important factors influencing the EBV DNA load in NPC patients. The results of the present study clearly showed a high association between pre-treatment EBV DNA load, the crucial classical prognostic factors (T, N, M and disease stage) of NPC and OS, suggesting that pre-treatment EBV DNA can be a useful prognostic biomarker in clinical decision-making and improving NPC treatment in Morocco.

中文翻译:

摩洛哥鼻咽癌患者体内循环性无细胞爱泼斯坦-巴尔病毒DNA水平和临床特征

鼻咽癌(NPC)的有效预后生物标志物的鉴定对于改善治疗和患者预后至关重要。在本研究中,我们试图评估摩洛哥人鼻咽癌患者血浆血浆爱泼斯坦-巴尔病毒(EBV)DNA载量与常规预后因素之间的相关性。本研究对2017年1月至2018年12月招募的121例经组织学证实的NPC患者进行了研究。在治疗开始前,使用实时定量PCR测量了EBV DNA的循环水平。总体而言,未分化的非角化癌类型是最常见的组织学类型(90.1%),并且61.8%的患者被诊断为处于疾病晚期(IV)。治疗前血浆EBV负荷的结果表明,有90.9%的患者具有可检测的EBV DNA,血浆病毒载量的中位数为7710 IU / ml。治疗前EBV DNA负荷与常规预后因素之间的相关性与患者年龄(p = 0.01),肿瘤分类(p = 0.01),淋巴结状态(p = 0.003),转移状态(p = 0.00)和整体癌症分期(p = 0.01)。出乎意料的是,在患有癌症家族史的NPC患者血浆中也发现了较高水平的治疗前EBV DNA(p = 0.04)。预处理EBVDNA水平高的患者的NPC死亡风险显着高于血浆EBV-DNA水平低的患者(p <0.05)。此外,治疗前EBV-DNA水平高的患者(≥2000,≥4000)的总生存率(OS)明显较低(p <0.05)。有趣的是,淋巴结受累 转移状态和OS被发现是影响NPC患者EBV DNA负荷的最重要因素。本研究的结果清楚地表明,治疗前EBV DNA负荷与NPC和OS的关键经典预后因素(T,N,M和疾病阶段)之间存在高度关联,这表明治疗前EBV DNA可能是有用的摩洛哥临床决策和改善NPC治疗中的预后生物标志物。
更新日期:2021-02-19
down
wechat
bug